Previous Close | 34.34 |
1-Year Change | -29.25% |
6-Months Change | -7.96% |
3-Months Change | -27.92% |
Moving Avg (50d) | 39.618 |
Moving Avg (200d) | 43.2 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.92B |
Beta (3-Years) | 0.8 |
Revenue Growth (ttm) | -29.75% |
Net Profit Margin (ttm) | -66.57% |
Return On Assets (ttm) | -13.96% |
EPS (ttm) | -2.87 |
PE Ratio (ttm) | -11.97 |
Dividend Yield | % |
Asset Description: | Ionis Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-03 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
36.108 | 37.17 | 37.878 | 38.94 | 40.71 | 42.48 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra and has four drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx... Wikipedia